Switch between JAK and TNF inhibitors safe, effective for rheumatoid arthritis

Reuters Health - 23/11/2020 - Rheumatoid arthritis patients who experience little or no reduction in symptoms from either Janus kinase (JAK) or tumor necrosis factor (TNF) inhibitor may achieve treatment goals by switching from one medicine to the other, a recent study suggests. Researchers randomized rheumatoid arthritis patients to receive adalimumab 40 mg (n=327) every other week; upadacitinib 15 mg (n=651) once daily; or placebo (n=651); for up to 26 weeks. They used a treat-to-target design, implementing blinded switching of patients from one therapy to the other prior to 26 weeks if they were non-responders, and at week 26 if they were incomplete responders. Switches were done immediately, without a washout period. Overall, a total of 252 patients who started on upadacitinib (39%) and 159 patients (49%) who started on adalimumab got switched to the other therapy due to nonresponse or incomplete response. Both groups of patients who switched from one the...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 23 November, 20205 December, 2020